| Bioactivity | SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 against SARS-CoV-2 by inhibiting of SKP2 protein and stabilizing BECN1[1]. |
| Name | SARS-CoV-2-IN-39 |
| CAS | 2882823-03-0 |
| Formula | C14H8ClF4NO3 |
| Molar Mass | 349.66 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rui Li, et al. Synthesis, cytotoxicity, and pharmacokinetic evaluations of niclosamide analogs for anti-SARS-CoV-2. Eur J Med Chem. 2023 May 5;253:115320. |
SARS-CoV-2-IN-39
CAS: 2882823-03-0 F: C14H8ClF4NO3 W: 349.66
SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 against SARS-CoV-2 by i
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.